In girls the visible pubertal development may be adequate, but menstruation is only achieved in half of the individuals. 4 The question of what is the ovarian reserve in girls and young women after HSCT is left unanswered. The classical tests used in the evaluation of the ovarian reserve have some inconveniences, especially in young patients after HSCT. Serum levels of follicle-stimulating hormone (FSH), Inhibin-B and estradiol (E2) are interdependent and should be performed in the early follicular phase. Nevertheless, the changes of serum levels of FSH, Inhibin-B and estradiol occur relatively late. It is not until age 7 years that elevated basal gonadotropins point to gonadal damage. 5 Moreover in young patients with low gonadotropins level, we cannot exclude the central or the composed etiology of hypogonadism. Assessment of the number of antral follicles by ultrasonography best predicts the quantitative aspect of ovarian reserve, 6 but using an transvaginal ultrasound during in the early follicular phase is often impossible in young females.
Anti-Muellerian hormone (AMH) is a relatively new marker of the ovarian function and the ovarian reserve. This is the serum marker that reflects the number of follicles that have made the transition from the primordial pool into the growing follicle pool, and that is not controlled by gonadotropins. 7 AMH is the earliest marker of diminishing ovarian reserve, with relatively minimal intra-and intercycle variation, and its serum levels decrease well before any increase in baseline FSH. 8 There is a transient rise in AMH in the neonatal period due to a transient activation of the reproductive axis at that time, followed by a more sustained rise through childhood and adolescence. Some studies reported that there is a plateau or even a decline in AMH during puberty. 9 AMH continues to rise after adolescence, with peak concentration, at approximately, the age of 24, and then decrease gradually with age, and the levels become undetectable after menopause. 10 AMH expression is affected relatively little by use of the oral or vaginal administration of synthetic sex steroids. 11 Additionally being not controlled by gonadotropins, AMH would benefit both patients and clinicians.
The aim of the study was to assess ovarian reserve in young patients after HSCT using evaluation of AMH hormone with comparison to classical hormonal tests.
Twenty-eight girls and women, mean 14.8 ± 5.0 year old, after HSCT, and 28 healthy girls and women, mean 15.3 ± 0.9 year old were included in the study (Table 1) . The Local Ethical Committee approved the study. The participants were consecutive female HSCT survivors during 2001-2014 from a single pediatric transplantation center, over 7 year old at the time of the recruiting Abbreviations: ABD = Blackfan-Diamond anemia; ALL = acute lymphoblastic leukemia; ATG = antithymocyte globulin; BEAM = carmustine (BiCNU), etoposide, cytarabine (Ara-C) and melphalan; Bu = busulphan; BuMel = busulphan, melphalan; Campath = alemtuzumab; CEM = cyclophosphamide, etoposide and melphalan; CGD = chronic granulomatous disease; CMV reactive. = cytomegalovirus reactivation; Cy = cyclophosphamide; FA = Fanconi anemia; GvHD = graft versus host disease; haplo = haploidentical; HD = Hodgkin disease; HRT = hormone replacement therapy; MSD = matched sibling donor; MUD = matched unrelated donor; NBL = neuroblastoma; NHL = non-Hodgkin lymphoma; rhGH = recombinant human growth hormone; SAA = severe aplastic anemia; SCID = severe combined immunodeficiency; SE = Sarcoma Ewing; TBI = total body irradiation, VP-16 = etposide.
to the study, who gave or whose parents gave their written, informed consents. The age of patients at transplantation time was mean 9.1 ± 5.0 years, the time from HSCT amounted mean 5.6 ± 3.7 years. The patients had been treated using HSCT due to different hematological (14) , oncologic (11) and non-malignant diseases (3). Autologous HSCTs (auto-HSCT) were performed in nine patients and allogeneic HSCTs (allo-HSCT) in 19. The details of the pretransplantation regimen and type of the graft are presented in Table 1 . Before the study, 13/28 patients had received hormone replacement therapy (HRT) to induce puberty (9) , and in the treatment of amenorrhea secundaria (4). Five of them discontinued HRT from different reasons, at least 6 months before the study. The spontaneous puberty after HSCT had been observed in three patients, the spontaneous menarche in one patient, and the recovery of normal menstrual cycles in three patients. Sexual development as prepubertal was assessed in 10 patients 7. AMH and Inhibin-B levels were significantly lower and FSH and LH levels were significantly higher in patients after HSCT than in age-matched healthy controls (Table 2 ). There were no differences in TSH, fT4, SHBG and PRL levels between HSCT patients and controls. Three patients in clinical and hormonal euthyreosis have positive anti-TPO antibodies. Clinical data on patients and results of ovarian function assessment are presented in Table 1 .
Decreased level of AMH was observed in 26/28 (90%) patients after HSCT. In 20/28 (71%) patients, AMH level was very low, below 0.08 ng/mL (6/9 in auto-HSCT group, 14/19 in allo-HSCT group). All auto-HSCT patients have decreased AMH levels, lower than the lowest level in the control group. Among patients after allo-HSCT, only two patients treated due to severe aplastic anemia have normal AMH, normal other hormones and normal menstruations. Six patients with AMH levels 0.14-0.87 ng/mL, presenting with prepubertal status with low FSH (3), spontaneous puberty (1) and normal menstruations (2), have normal Inhibin-B level. On the base of AMH level measurement, decreased ovarian reserve and abnormal ovarian function can be diagnosed in 90% of patients after HSCT.
Nineteen/28 patients (68%) had Inhibin-B level lower than the lowest inhibin level in the control group. Twenty-four/28 (86%) patients after HSCT had Inhibin-B level lower than 40 pg/mL, what result allows to diagnose impaired ovarian function and decreased ovarian reserve. 12 Eighteen/28 patients presented with hypergonadotropic hypogonadism, 3/28 have prepubertal values of sex hormones with elevated FSH (together 75%), 7/28 (25%) patients have normal values of sex hormones (including 3/28 prepubertal). On the base of the results of gonadotropins, abnormal ovarian function and decrease ovarian reserve can be diagnosed in 75% of patients after HSCT.
The decreased ovarian reserve after HSCT may present with disturbances of puberty, previous ovarian dysfunction, or also can be clinically asymptomatic. These disturbances can occur as a result of impairment at the level of the regulatory central unit, or at the level of the gonads. On the base of our data, ovaries are more vulnerable during HSCT procedure than the central unit. Hypergonadotropic hypogonadism was diagnosed in most of our patients. In three of our prepubertal patients with low AMH level without elevated FSH, we can probably diagnose a composed hypogonadism. The pretransplantation conditioning regiment is still considered as a main cause of hypogonadism after HSCT. Most of our patients after high-dose chemotherapy have decreased ovary reserve on the base of AMH level in spite of normal or subnormal puberty outcome, and even spontaneous menarche and regular menstruation cycles in some cases. All eight girls, who underwent TBI needed HRT to induce puberty or to restore normal menstruation cycles and presented with low value of AMH and Inhibin-B. Basing on the data of the patients involved assisted reproductive technology, the clinical pregnancy rate was higher among women, a random serum AMH level of 0.6 ng/mL or higher compared with women with a random serum AMH below 0.6 ng/mL. 13 Only 3/28 (10%) of our patients have AMH level above 0.6 mg/mL. All these patients received HSCT due to severe aplastic anemia, therefore had not received antiblastic agents in pretransplant period.
The good experience with using AMH level in the assessment of ovarian reserve in young women after treatment for cancer in childhood was reported by other authors. Miyoshi et al.
14 underlined the role of AMH evaluation in detecting of primary gonadal deficiency, particularly among patients without increased gonadotropin levels. Bath et al. 15 indicated the possibility of assessment of ovary reserve using AMH level also in women receiving HRT. Our study has some limitations. It was impossible to get the pretreatment values of AMH. Some of recruited patients were prepubertal and the assessment of AMH in very young girls should be with the understanding that it may still be rising.
Our study results demonstrate that in young women, HSCT recipients AMH is independent and more sensitive and specific test than other markers in the evaluation of ovarian function and reserve after HSCT. The measurement of AMH level allows to suspect hypogonadism in prepubertal girls, to diagnose central or composed hypogonadism, moreover lets to diagnose the ovarian function and the ovarian reserve in the patients receiving HRT, without discontinuation of this therapy.
